1. Home
  2. REPL vs BOE Comparison

REPL vs BOE Comparison

Compare REPL & BOE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • REPL
  • BOE
  • Stock Information
  • Founded
  • REPL 2015
  • BOE 2005
  • Country
  • REPL United States
  • BOE United States
  • Employees
  • REPL N/A
  • BOE N/A
  • Industry
  • REPL Biotechnology: Pharmaceutical Preparations
  • BOE Trusts Except Educational Religious and Charitable
  • Sector
  • REPL Health Care
  • BOE Finance
  • Exchange
  • REPL Nasdaq
  • BOE Nasdaq
  • Market Cap
  • REPL 547.0M
  • BOE 643.8M
  • IPO Year
  • REPL 2018
  • BOE N/A
  • Fundamental
  • Price
  • REPL $10.07
  • BOE $11.64
  • Analyst Decision
  • REPL Buy
  • BOE
  • Analyst Count
  • REPL 9
  • BOE 0
  • Target Price
  • REPL $10.88
  • BOE N/A
  • AVG Volume (30 Days)
  • REPL 8.8M
  • BOE 166.1K
  • Earning Date
  • REPL 11-07-2025
  • BOE 01-01-0001
  • Dividend Yield
  • REPL N/A
  • BOE 7.30%
  • EPS Growth
  • REPL N/A
  • BOE N/A
  • EPS
  • REPL N/A
  • BOE N/A
  • Revenue
  • REPL N/A
  • BOE N/A
  • Revenue This Year
  • REPL N/A
  • BOE N/A
  • Revenue Next Year
  • REPL N/A
  • BOE N/A
  • P/E Ratio
  • REPL N/A
  • BOE N/A
  • Revenue Growth
  • REPL N/A
  • BOE N/A
  • 52 Week Low
  • REPL $2.68
  • BOE $8.80
  • 52 Week High
  • REPL $17.00
  • BOE $10.48
  • Technical
  • Relative Strength Index (RSI)
  • REPL 75.32
  • BOE 53.84
  • Support Level
  • REPL $7.69
  • BOE $11.47
  • Resistance Level
  • REPL $10.85
  • BOE $11.71
  • Average True Range (ATR)
  • REPL 0.67
  • BOE 0.13
  • MACD
  • REPL 0.48
  • BOE 0.01
  • Stochastic Oscillator
  • REPL 88.10
  • BOE 65.52

About REPL Replimune Group Inc.

Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.

About BOE Blackrock Enhanced Global Dividend Trust of Beneficial Interest

Blackrock Enhanced Global Dividend Trust has an investment objective to provide current income and current gains, with a secondary investment objective of long-term capital appreciation. Further, it focuses on investing in a portfolio of equity securities and utilizing an option writing to seek total return performance and enhance distributions.

Share on Social Networks: